Afya Board Member Maria Tereza Azevedo Resigns, Impacting Decision-Making Diversity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy AFYA?
Source: Newsfilter
- Board Changes: Afya announced that board member Maria Tereza Azevedo will resign effective December 31, 2025, which may impact the diversity and stability of the company's decision-making processes.
- Board Structure: The current board consists of two co-chairmen and several independent directors, ensuring a diverse range of skills and experiences that enhance Afya's decision-making quality.
- Company Background: Afya is a leading medical education group in Brazil, providing a comprehensive ecosystem from medical education to practice solutions, dedicated to supporting the career development of students and physicians.
- Future Outlook: Despite the board member change, Afya will continue to focus on its mission to enhance physicians' careers through high-quality education and healthcare services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFYA
Wall Street analysts forecast AFYA stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 14.750
Low
16.00
Averages
18.90
High
22.00
Current: 14.750
Low
16.00
Averages
18.90
High
22.00
About AFYA
Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Afya Ltd Reports Strong Growth in Earnings Call
- Significant Revenue Growth: Afya Ltd reported revenue of BRL 3.697 billion, marking a 12% year-over-year increase, indicating sustained demand and market leadership in medical education.
- Substantial EBITDA Increase: Adjusted EBITDA reached BRL 1.68 billion, growing over 50% year-over-year, with an EBITDA margin increase to 45.4%, showcasing the company's success in cost control and operational efficiency.
- Strong Cash Flow Performance: Cash flow from operating activities amounted to BRL 1.548 billion, a 6% increase from the previous year, providing a solid foundation for future investments and shareholder returns, reflecting the company's financial health.
- Commitment to Shareholder Returns: The company announced a cash dividend of BRL 307.4 million, equivalent to $0.45 per share, demonstrating a strong commitment to shareholder returns while also providing funding for future growth investments.
See More
Afyapress Releases Q4 2024 Financial Results
- Strong Financial Performance: Afyapress reported a Q4 Non-GAAP EPS of R$2.25 with revenue of R$912.99 million, reflecting a 7.5% year-over-year growth, indicating robust market growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased by 6.1% to R$388.5 million, with an adjusted EBITDA margin of 42.6%, demonstrating effective management in cost control and profitability.
- Outstanding Cash Flow: The operating cash conversion ratio stood at 93.7%, with record free cash flow of R$1,056 million and a solid cash position of R$1,125.4 million, ensuring financial flexibility for future investments and operations.
- Positive 2026 Outlook: Building on a solid foundation from 2025 guidance achievements, Afyapress expects 2026 revenue to range between R$3,950 million and R$4,100 million, with adjusted EBITDA projected between R$1,700 million and R$1,800 million, reflecting confidence in future growth.
See More
Afya Reports Strong Earnings Beat, Positive Outlook Ahead
- Earnings Surprise: Afya reported earnings of $0.41 per share, exceeding the Zacks consensus estimate of $0.38, and up from $0.36 a year ago, indicating a solid improvement in profitability that is likely to boost investor confidence.
- Revenue Miss: Despite the earnings beat, Afya's quarterly revenue of $169.03 million fell short of the Zacks consensus estimate by 4.57%, highlighting challenges in revenue growth that could impact future market performance.
- Market Performance Analysis: Afya's shares have declined approximately 9.9% since the beginning of the year, compared to a 1% drop in the S&P 500, indicating relative weakness in the market, prompting investors to closely monitor future earnings expectations and industry trends.
- Outlook: The current consensus EPS estimate for Afya is $0.54 with projected revenues of $192.58 million, reflecting market confidence in the company's growth potential, and with a Zacks Rank of #2 (Buy), it suggests competitive strength and potential upside in the industry.
See More
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
AFYA LTD Reports Q4 Basic Earnings Per Share of R$1.91
- Earnings Report: The company reported basic earnings per share of $1.91 for the fourth quarter.
- Financial Performance: This figure reflects the company's financial performance during the specified period.
See More
AFYA LTD PROJECTS FY 2026 REVENUE BETWEEN R$3.95 BILLION AND R$4.1 BILLION, WITH ADJUSTED EBITDA EXPECTED TO RANGE FROM R$1.7 BILLION TO R$1.8 BILLION
- Revenue Expectations: Revenue for FY 2026 is projected to range between R$3,950 million and R$4,100 million.
- Adjusted EBITDA Forecast: Adjusted EBITDA is expected to be between R$1,700 million and R$1,800 million.
See More
Afya Ltd Reports Strong Growth in Earnings Call
- Significant Revenue Growth: Afya Ltd reported revenue of BRL 3.697 billion, marking a 12% year-over-year increase, indicating sustained demand and market leadership in medical education.
- Substantial EBITDA Increase: Adjusted EBITDA reached BRL 1.68 billion, growing over 50% year-over-year, with an EBITDA margin increase to 45.4%, showcasing the company's success in cost control and operational efficiency.
- Strong Cash Flow Performance: Cash flow from operating activities amounted to BRL 1.548 billion, a 6% increase from the previous year, providing a solid foundation for future investments and shareholder returns, reflecting the company's financial health.
- Commitment to Shareholder Returns: The company announced a cash dividend of BRL 307.4 million, equivalent to $0.45 per share, demonstrating a strong commitment to shareholder returns while also providing funding for future growth investments.
See More
Afyapress Releases Q4 2024 Financial Results
- Strong Financial Performance: Afyapress reported a Q4 Non-GAAP EPS of R$2.25 with revenue of R$912.99 million, reflecting a 7.5% year-over-year growth, indicating robust market growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased by 6.1% to R$388.5 million, with an adjusted EBITDA margin of 42.6%, demonstrating effective management in cost control and profitability.
- Outstanding Cash Flow: The operating cash conversion ratio stood at 93.7%, with record free cash flow of R$1,056 million and a solid cash position of R$1,125.4 million, ensuring financial flexibility for future investments and operations.
- Positive 2026 Outlook: Building on a solid foundation from 2025 guidance achievements, Afyapress expects 2026 revenue to range between R$3,950 million and R$4,100 million, with adjusted EBITDA projected between R$1,700 million and R$1,800 million, reflecting confidence in future growth.
See More
Afya Reports Strong Earnings Beat, Positive Outlook Ahead
- Earnings Surprise: Afya reported earnings of $0.41 per share, exceeding the Zacks consensus estimate of $0.38, and up from $0.36 a year ago, indicating a solid improvement in profitability that is likely to boost investor confidence.
- Revenue Miss: Despite the earnings beat, Afya's quarterly revenue of $169.03 million fell short of the Zacks consensus estimate by 4.57%, highlighting challenges in revenue growth that could impact future market performance.
- Market Performance Analysis: Afya's shares have declined approximately 9.9% since the beginning of the year, compared to a 1% drop in the S&P 500, indicating relative weakness in the market, prompting investors to closely monitor future earnings expectations and industry trends.
- Outlook: The current consensus EPS estimate for Afya is $0.54 with projected revenues of $192.58 million, reflecting market confidence in the company's growth potential, and with a Zacks Rank of #2 (Buy), it suggests competitive strength and potential upside in the industry.
See More
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
AFYA LTD Reports Q4 Basic Earnings Per Share of R$1.91
- Earnings Report: The company reported basic earnings per share of $1.91 for the fourth quarter.
- Financial Performance: This figure reflects the company's financial performance during the specified period.
See More
AFYA LTD PROJECTS FY 2026 REVENUE BETWEEN R$3.95 BILLION AND R$4.1 BILLION, WITH ADJUSTED EBITDA EXPECTED TO RANGE FROM R$1.7 BILLION TO R$1.8 BILLION
- Revenue Expectations: Revenue for FY 2026 is projected to range between R$3,950 million and R$4,100 million.
- Adjusted EBITDA Forecast: Adjusted EBITDA is expected to be between R$1,700 million and R$1,800 million.
See More
